Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Fri, 28.06.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D [ … ]
Fri, 28.06.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D [ … ]
Thu, 13.06.2024
Formycon AG
Press Release // June 13, 2024
Formycon reports on the results of the Annual General Meeting
Management provides detailed report on financial year 2023 and current company performance
Shareholders approve all agenda items and formally approve the acts of the members of the Management Board and Supervisory Board by large majority
Supervisory Boa [ … ]
Thu, 13.06.2024
Formycon AG
First Berlin Equity Research has published a research update on Formycon AG
(ISIN: DE000A1EWVY8). Analyst Simon Scholes reiterated his BUY rating and
decreased the price target from EUR 105.00 to EUR 80.00.
Abstract:
The Formycon share price has fallen by more than 40% since the beginning of
2023, mainly because of lower than expected royalty i [ … ]
Thu, 13.06.2024
Formycon AG
Press Release // June 13, 2024
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
First patient entered Phase I clinical trial “Dahlia” to compare the pharmacokinetics (PK), safety and tolerability of FYB206 with the reference product Keytruda®[i] (First Patient In).
"Dah [ … ]
Wed, 15.05.2024
Formycon AG
Presse Release // May 15, 2024
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Planegg-Martinsried – Klinge Biopharma GmbH ("Klinge"), licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to [ … ]
Wed, 15.05.2024
Formycon AG
Presse Release // May 15, 2024
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Planegg-Martinsried – Klinge Biopharma GmbH ("Klinge"), licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to [ … ]
Wed, 08.05.2024
Formycon AG
Press Release // May 8, 2024
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Group revenue amounts to € 17.7 million and corresponds to plan
Group EBITDA of € -5.5 million reflects investments in pipeline and corporate development
Adjusted Group EBITDA of € -1.2 million shows strong at-equi [ … ]
Tue, 07.05.2024
Formycon AG
Press release // 07 May 2024
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
Formycon proposes to the Annual General Meeting a more international focus and expansion of the Supervisory Board to five members
With Colin Bond, Dr. Bodo Coldewey and Nicholas Haggar, three new candidates with relevant industry and financial [ … ]
Thu, 02.05.2024
Formycon AG
Press Release // May 02, 2024
Formycon hosts conference call on the results of the first quarter 2024
Planegg-Martinsried – Formycon AG (FWB: FYB, 'Formycon') today announced details of the conference call to release the results of the first quarter 2024 on May 08, 2024. The management board will discuss the company's developments and key financi [ … ]